Trajenta meets primary endpoint in CAROLINA trial
Eli Lilly and Boehringer Ingelheim’s Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk.
Read More
Tag: CAROLINA
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
